ArticleFrontiers in immunology2023

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.

Yifan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.